<?xml version='1.0' encoding='utf-8'?>
<document id="31036687"><sentence text="Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay." /><sentence text="Buruli ulcer is treatable with antibiotics" /><sentence text=" An 8-week course of rifampin (RIF) and either streptomycin (STR) or clarithromycin (CLR) cures over 90% of patients"><entity charOffset="21-29" id="DDI-PubMed.31036687.s3.e0" text="rifampin" /><entity charOffset="31-34" id="DDI-PubMed.31036687.s3.e1" text="RIF" /><entity charOffset="47-59" id="DDI-PubMed.31036687.s3.e2" text="streptomycin" /><entity charOffset="61-64" id="DDI-PubMed.31036687.s3.e3" text="STR" /><entity charOffset="69-83" id="DDI-PubMed.31036687.s3.e4" text="clarithromycin" /><entity charOffset="85-88" id="DDI-PubMed.31036687.s3.e5" text="CLR" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e0" e2="DDI-PubMed.31036687.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e0" e2="DDI-PubMed.31036687.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e0" e2="DDI-PubMed.31036687.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e0" e2="DDI-PubMed.31036687.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e0" e2="DDI-PubMed.31036687.s3.e4" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e0" e2="DDI-PubMed.31036687.s3.e5" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e1" e2="DDI-PubMed.31036687.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e1" e2="DDI-PubMed.31036687.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e1" e2="DDI-PubMed.31036687.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e1" e2="DDI-PubMed.31036687.s3.e4" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e1" e2="DDI-PubMed.31036687.s3.e5" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e2" e2="DDI-PubMed.31036687.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e2" e2="DDI-PubMed.31036687.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e2" e2="DDI-PubMed.31036687.s3.e4" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e2" e2="DDI-PubMed.31036687.s3.e5" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e3" e2="DDI-PubMed.31036687.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e3" e2="DDI-PubMed.31036687.s3.e4" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e3" e2="DDI-PubMed.31036687.s3.e5" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e4" e2="DDI-PubMed.31036687.s3.e4" /><pair ddi="false" e1="DDI-PubMed.31036687.s3.e4" e2="DDI-PubMed.31036687.s3.e5" /></sentence><sentence text=" However, STR requires injections and may be toxic, and CLR shares an adverse drug-drug interaction with RIF and may be poorly tolerated"><entity charOffset="105-107" id="DDI-PubMed.31036687.s4.e0" text="RIF" /><entity charOffset="10-12" id="DDI-PubMed.31036687.s4.e1" text="STR" /><entity charOffset="56-58" id="DDI-PubMed.31036687.s4.e2" text="CLR" /><pair ddi="false" e1="DDI-PubMed.31036687.s4.e1" e2="DDI-PubMed.31036687.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31036687.s4.e1" e2="DDI-PubMed.31036687.s4.e2" /><pair ddi="true" e1="DDI-PubMed.31036687.s4.e1" e2="DDI-PubMed.31036687.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31036687.s4.e2" e2="DDI-PubMed.31036687.s4.e2" /><pair ddi="true" e1="DDI-PubMed.31036687.s4.e2" e2="DDI-PubMed.31036687.s4.e0" /></sentence><sentence text=" Studies in a mouse footpad infection model showed that increasing the dose of RIF or using the long-acting rifamycin rifapentine (RPT), in combination with clofazimine (CFZ), a relatively well-tolerated antibiotic, can shorten treatment to 4 weeks"><entity charOffset="108-129" id="DDI-PubMed.31036687.s5.e0" text="rifamycin rifapentine" /><entity charOffset="131-134" id="DDI-PubMed.31036687.s5.e1" text="RPT" /><entity charOffset="157-168" id="DDI-PubMed.31036687.s5.e2" text="clofazimine" /><entity charOffset="170-173" id="DDI-PubMed.31036687.s5.e3" text="CFZ" /><entity charOffset="79-81" id="DDI-PubMed.31036687.s5.e4" text="RIF" /><pair ddi="false" e1="DDI-PubMed.31036687.s5.e4" e2="DDI-PubMed.31036687.s5.e4" /><pair ddi="false" e1="DDI-PubMed.31036687.s5.e4" e2="DDI-PubMed.31036687.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31036687.s5.e4" e2="DDI-PubMed.31036687.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31036687.s5.e4" e2="DDI-PubMed.31036687.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31036687.s5.e4" e2="DDI-PubMed.31036687.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31036687.s5.e0" e2="DDI-PubMed.31036687.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31036687.s5.e0" e2="DDI-PubMed.31036687.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31036687.s5.e0" e2="DDI-PubMed.31036687.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31036687.s5.e0" e2="DDI-PubMed.31036687.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31036687.s5.e1" e2="DDI-PubMed.31036687.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31036687.s5.e1" e2="DDI-PubMed.31036687.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31036687.s5.e1" e2="DDI-PubMed.31036687.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31036687.s5.e2" e2="DDI-PubMed.31036687.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31036687.s5.e2" e2="DDI-PubMed.31036687.s5.e3" /></sentence><sentence text=" CFZ is reduced by a component of the electron transport chain (ETC) to produce reactive oxygen species toxic to bacteria"><entity charOffset="89-95" id="DDI-PubMed.31036687.s6.e0" text="oxygen" /><entity charOffset="1-6" id="DDI-PubMed.31036687.s6.e1" text="CFZ" /><pair ddi="false" e1="DDI-PubMed.31036687.s6.e1" e2="DDI-PubMed.31036687.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31036687.s6.e1" e2="DDI-PubMed.31036687.s6.e0" /></sentence><sentence text=" Synergistic activity of CFZ with other ETC-targeting drugs, the ATP synthase inhibitor bedaquiline (BDQ) and the bc1:aa3 oxidase inhibitor Q203 (now named telacebec), was recently described against Mycobacterium tuberculosis Recognizing that M"><entity charOffset="65-68" id="DDI-PubMed.31036687.s7.e0" text="ATP" /><entity charOffset="88-99" id="DDI-PubMed.31036687.s7.e1" text="bedaquiline" /><entity charOffset="101-104" id="DDI-PubMed.31036687.s7.e2" text="BDQ" /><entity charOffset="25-27" id="DDI-PubMed.31036687.s7.e3" text="CFZ" /><pair ddi="false" e1="DDI-PubMed.31036687.s7.e3" e2="DDI-PubMed.31036687.s7.e3" /><pair ddi="false" e1="DDI-PubMed.31036687.s7.e3" e2="DDI-PubMed.31036687.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31036687.s7.e3" e2="DDI-PubMed.31036687.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31036687.s7.e3" e2="DDI-PubMed.31036687.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31036687.s7.e0" e2="DDI-PubMed.31036687.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31036687.s7.e0" e2="DDI-PubMed.31036687.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31036687.s7.e0" e2="DDI-PubMed.31036687.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31036687.s7.e1" e2="DDI-PubMed.31036687.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31036687.s7.e1" e2="DDI-PubMed.31036687.s7.e2" /></sentence><sentence text=" tuberculosis mutants lacking the alternative bd oxidase are hypersusceptible to Q203 and that Mycobacterium ulcerans is a natural bd oxidase-deficient mutant, we tested the in vitro susceptibility of M" /><sentence text=" ulcerans to Q203 and evaluated the treatment-shortening potential of novel 3- and 4-drug regimens combining RPT, CFZ, Q203, and/or BDQ in a mouse footpad model"><entity charOffset="109-111" id="DDI-PubMed.31036687.s9.e0" text="RPT" /><entity charOffset="114-116" id="DDI-PubMed.31036687.s9.e1" text="CFZ" /><entity charOffset="132-134" id="DDI-PubMed.31036687.s9.e2" text="BDQ" /><pair ddi="false" e1="DDI-PubMed.31036687.s9.e0" e2="DDI-PubMed.31036687.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31036687.s9.e0" e2="DDI-PubMed.31036687.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31036687.s9.e0" e2="DDI-PubMed.31036687.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31036687.s9.e1" e2="DDI-PubMed.31036687.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31036687.s9.e1" e2="DDI-PubMed.31036687.s9.e2" /></sentence><sentence text=" The MIC of Q203 was extremely low (0" /><sentence text="000075 to 0" /><sentence text="00015 μg/ml)" /><sentence text=" Footpad swelling decreased more rapidly in mice treated with Q203-containing regimens than in mice treated with RIF and STR (RIF+STR) and RPT and CFZ (RPT+CFZ)"><entity charOffset="113-115" id="DDI-PubMed.31036687.s13.e0" text="RIF" /><entity charOffset="126-128" id="DDI-PubMed.31036687.s13.e1" text="RIF" /><entity charOffset="121-123" id="DDI-PubMed.31036687.s13.e2" text="STR" /><entity charOffset="130-132" id="DDI-PubMed.31036687.s13.e3" text="STR" /><entity charOffset="139-141" id="DDI-PubMed.31036687.s13.e4" text="RPT" /><entity charOffset="152-154" id="DDI-PubMed.31036687.s13.e5" text="RPT" /><entity charOffset="147-149" id="DDI-PubMed.31036687.s13.e6" text="CFZ" /><entity charOffset="156-158" id="DDI-PubMed.31036687.s13.e7" text="CFZ" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e0" e2="DDI-PubMed.31036687.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e0" e2="DDI-PubMed.31036687.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e0" e2="DDI-PubMed.31036687.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e0" e2="DDI-PubMed.31036687.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e0" e2="DDI-PubMed.31036687.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e0" e2="DDI-PubMed.31036687.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e0" e2="DDI-PubMed.31036687.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e0" e2="DDI-PubMed.31036687.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e2" e2="DDI-PubMed.31036687.s13.e2" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e2" e2="DDI-PubMed.31036687.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e2" e2="DDI-PubMed.31036687.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e2" e2="DDI-PubMed.31036687.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e2" e2="DDI-PubMed.31036687.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e2" e2="DDI-PubMed.31036687.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e2" e2="DDI-PubMed.31036687.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e1" e2="DDI-PubMed.31036687.s13.e1" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e1" e2="DDI-PubMed.31036687.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e1" e2="DDI-PubMed.31036687.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e1" e2="DDI-PubMed.31036687.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e1" e2="DDI-PubMed.31036687.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e1" e2="DDI-PubMed.31036687.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e3" e2="DDI-PubMed.31036687.s13.e3" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e3" e2="DDI-PubMed.31036687.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e3" e2="DDI-PubMed.31036687.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e3" e2="DDI-PubMed.31036687.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e3" e2="DDI-PubMed.31036687.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e4" e2="DDI-PubMed.31036687.s13.e4" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e4" e2="DDI-PubMed.31036687.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e4" e2="DDI-PubMed.31036687.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e4" e2="DDI-PubMed.31036687.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e6" e2="DDI-PubMed.31036687.s13.e6" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e6" e2="DDI-PubMed.31036687.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e6" e2="DDI-PubMed.31036687.s13.e7" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e5" e2="DDI-PubMed.31036687.s13.e5" /><pair ddi="false" e1="DDI-PubMed.31036687.s13.e5" e2="DDI-PubMed.31036687.s13.e7" /></sentence><sentence text=" Nearly all footpads were culture negative after only 2 weeks of treatment with regimens containing RPT, CFZ, and Q203"><entity charOffset="100-102" id="DDI-PubMed.31036687.s14.e0" text="RPT" /><entity charOffset="105-107" id="DDI-PubMed.31036687.s14.e1" text="CFZ" /><pair ddi="false" e1="DDI-PubMed.31036687.s14.e0" e2="DDI-PubMed.31036687.s14.e0" /><pair ddi="false" e1="DDI-PubMed.31036687.s14.e0" e2="DDI-PubMed.31036687.s14.e1" /></sentence><sentence text=" No relapse was detected after only 2 weeks of treatment in mice treated with any of the Q203-containing regimens" /><sentence text=" In contrast, 15% of mice receiving RIF+STR for 4 weeks relapsed"><entity charOffset="36-38" id="DDI-PubMed.31036687.s16.e0" text="RIF" /><entity charOffset="40-42" id="DDI-PubMed.31036687.s16.e1" text="STR" /><pair ddi="false" e1="DDI-PubMed.31036687.s16.e0" e2="DDI-PubMed.31036687.s16.e0" /><pair ddi="false" e1="DDI-PubMed.31036687.s16.e0" e2="DDI-PubMed.31036687.s16.e1" /></sentence><sentence text=" We conclude that it may be possible to cure patients with Buruli ulcer in 14 days or less using Q203-containing regimens rather than currently recommended 56-day regimens" /><sentence text="" /></document>